...
首页> 外文期刊>International journal of infectious diseases : >Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys? anti-SARS-CoV-2 immunoassay
【24h】

Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys? anti-SARS-CoV-2 immunoassay

机译:用罗氏elecsys作为简单评估策略的点普遍的特异性测试? 抗SARS-COV-2免疫测定

获取原文
           

摘要

Background The detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mandatory for the diagnosis, retrospective assessment of disease progression, and correct evaluation of the current infection situation in the population. Many such assays have been launched by various manufacturers. Unfortunately, the new US Food and Drug Administration emergency use regulations have resulted in a situation where laboratories have to perform their own validation studies but many of these laboratories do not have the biobank needed to conduct the studies. Methods We introduce a method that allows institutions to quickly perform a verification study in a low-prevalence infection situation. As proof of concept, we used the Roche Elecsys? anti-SARS-CoV-2 electrochemiluminescence immunoassay and an SAP-based hospital information system. The Shenzhen YHLO Biotech IgM and IgG assay targeting other surface patterns was used as a confirmatory test. Results The Roche assay demonstrated a limit of detection of 0.069 cutoff index and successfully passed the performance validation according to Clinical and Laboratory Standards Institute EP15-A3. The study population of 627 inpatients has a median age of 64 years, and approximately 13% of the group were under intensive care at the respective time point. All patients included tested negative for SARS-CoV-2 infection by quantitative reverse transcription polymerase chain reaction (cobas? 6800, Roche, Mannheim, Germany). Only one false-positive result was obtained, resulting in a specificity for the Roche Elecsys anti-SARS-CoV-2 test of 99.84% and a negative predictive value of 99.98%. Conclusions The anonymized use of residual material enables quick evaluation of anti-SARS-CoV-2 immunoassays, as shown in this work with the Roche Elecsys assay. Comparison of the control population with economic data makes it possible to validate the sampling set and therefore to determine diagnostic specificity. By use of the approach chosen, it was shown that the Roche test achieved very good results in terms of diagnostic specificity, reproducibility, and limit of detection.
机译:背景技术对严重急性呼吸综合征冠状病毒2(SARS-COV-2)的抗体的检测是诊断,回顾性评估疾病进展的诊断,以及对当前人口感染情况进行评估。许多这样的测定由各种制造商推出。不幸的是,新的美国食品和药物管理局紧急使用法规导致了实验室必须履行自己的验证研究,但许多这些实验室没有BioBank需要进行研究。方法介绍一种允许机构在低流行感染情况下快速进行验证研究的方法。作为概念证明,我们使用了罗氏elecsys?抗SARS-COV-2电化学荧光免疫测定和基于SAP的医院信息系统。靶向其他表面图案的深圳Yhlo Biotech IgM和IgG测定用作确认测试。结果罗氏测定显示了0.069截止指数的检测限,并根据临床和实验室标准研究所EP15-A3成功通过了性能验证。 627名住院患者的研究人群中位数年龄为64岁,大约13%的小组在相应的时间点进行了重症监护权。所有患者通过定量逆转录聚合酶链反应(COBASα6800,罗氏,曼海姆,德国),所有患者都对SARS-COV-2感染进行了检测阴性。只获得一个假阳性结果,导致Roche Elecsys抗SARS-COV-2试验的特异性为99.84%,负预测值为99.98%。结论匿名使用残留物质可以快速评估抗SARS-COV-2免疫测定,如此合适的roche Elecsys测定所示。控制群体与经济数据的比较使得可以验证采样集,从而确定确定诊断特异性。通过使用所选择的方法,显示Roche测试在诊断特异性,再现性和检测极限方面实现了非常好的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号